P. А. Shesternya

A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis

Dae‐Hyun Yoo, Chang‐Hee Suh, Seung Cheol Shim et al. · Annals of the Rheumatic Diseases · 2016 · 81 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial

René Westhovens, Piotr Wiland, Marek Zawadzki et al. · Lara D. Veeken · 2020 · 56 citations · Full text

Medicine, Pharmacokinetics, Pharmacotherapy +14

Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial

Won Park, Ljubinka Božić-Majstorović, Dragana Milaković et al. · mAbs · 2018 · 52 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacotherapy +17

Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial

Seung Cheol Shim, Ljubinka Božić-Majstorović, Alfredo Berrocal Kasay et al. · Lara D. Veeken · 2019 · 47 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +16

Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis

Won Park, Chang‐Hee Suh, Seung Cheol Shim et al. · BioDrugs · 2017 · 43 citations · Full text

Medicine, Pharmacotherapy, Immunotherapy +11